Rituximab, sold under the brand name Rituxan, is a monoclonal antibody used to treat certain autoimmune diseases and types of cancer. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences.
Rituximab Biosimilar Antibody
$205.00 – $2,500.00
Rituximab is a chimeric murine/human immunoglobulin (Ig) G1-kappa monoclonal antibody against human CD20 protein.
Host/Isotype: Human/Murine chimera/IgG1
Class: Monoclonal
Immunogen: Human CD20 protein
Production platform: CHO cells
Purification: Affinity chromatography
Storage buffer: PBS, pH 7.2
Storage condition: –20°C
For Research Use Only. Not for use in clinical diagnostics or therapeutics.
Additional information
Antibody Production Scale | 50 ug, 250 ug, 1 mg |
---|---|
Conjugate | None, FITC, HRP, ADC (custom drug) |
You must be logged in to post a review.
Reviews
There are no reviews yet.